COMMUNIQUÉS West-GlobeNewswire

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer’s Disease
31/01/2019
Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision TORONTO and CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- ProMIS [...]
Nash Pharmaceuticals to Present Pre-Clinical Data on Non-Alcoholic Fatty Liver Disease at 2nd Global NASH Congress in London, UK
31/01/2019
VANCOUVER, British Columbia, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (the “ Company ” or “Nash Pharma”) is pleased to [...]
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019
31/01/2019
CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company [...]
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 7, 2019
31/01/2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV [...]
Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals
31/01/2019
Fortress-founded Caelum Biosciences to receive $60 million in a strategic equity investment and option fee Alexion has option to acquire Caelum Biosciences based on Phase 2 data NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE [...]
Quotient Limited Provides an Update on Extended Immunohematology Microarray Performance and on the Commencement of the Initial Serological Disease Screening Field Trial together with Third Quarter Fiscal 2019 Results
31/01/2019
Development data provides positive results for extended IH microarray panel Field trial for initial Serological Disease microarray panel has commenced Reagent revenue growth of 15% in the quarter and 12% year to date [...]
Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
31/01/2019
- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition - - Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 - NEW HAVEN, Conn., Jan. 31, 2019 ( [...]
Wright Medical Group N.V. Announces Privately Negotiated Exchange of Wright Medical Group, Inc.’s 2.00% Cash Convertible Senior Notes due 2020 for its 1.625% Cash Convertible Senior Notes due 2023
31/01/2019
AMSTERDAM, The Netherlands, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ: WMGI) (the “Company”) today announced that it has entered into privately negotiated agreements among the Company, Wright [...]
Business Development Director Lea Paloheimo will retire from Biohit Oyj
31/01/2019
Biohit Oyj 31.01.2019 at 12:00 local time (EST) Biohit’s management team member Business Development Director Lea Paloheimo will retire as planned 31 st of January 2019. Lea Paloheimo has been employed by Biohit since [...]
Registration of the quantity of shares in Nexstim Plc
31/01/2019
Company Announcement, Helsinki, 31.1.2019 at 11.30 Registration of the quantity of shares in Nexstim Plc The Extraordinary General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company [...]
Change to the Board of Directors
31/01/2019
Mrs. Patricia Malarkey resigns from the Board of Directors of Novozymes A/S. Read the full announcement in PDF. Attachment 2019_02_Change_to_the_BoD_EN
DrugCendR Announces Pancreatic Cancer Clinical Trial Data, New Member of Board of Directors and FDA Orphan Drug Designation
31/01/2019
LA JOLLA, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the barriers of drug delivery [...]
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care
31/01/2019
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care Lugano, Switzerland, January 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care [...]
Capital increase of 26,060 shares (equivalent to approximately 0.13% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
31/01/2019
Orphazyme A/S Company announcement No. 03/2019 Company Registration No. 32266355 Copenhagen, Denmark, January 31 , 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments [...]
Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue
31/01/2019
Press Release 31 January 2019 Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue Immunicum AB (publ) (the "Company" or "Immunicum") has, as previously announced, implemented a share [...]
Olainfarm will supply anti-tuberculosis drugs to the WHO for more than 1 million dollars
31/01/2019
Based on a cooperation agreement concluded last year, in the 1st quarter of 2019 JSC Olainfarm will be delivering its PAS- sodium anti-tuberculosis medicine, to the World Health Organisation (WHO) for a total of more [...]
Financière de Tubize SA : Cancellation of own shares - New denominator
31/01/2019
Press release 31st January 2019 - 8:00h CET FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, general manager, aspijcke@icloud.com Cancellation of own shares New denominator [...]
Financière de Tubize SA : Annulation d'actions propres - Nouveau dénominateur
31/01/2019
Communiqué de presse 31 janvier 2019 - 8:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: Anne Sophie Pijcke, aspijcke@icloud.com Annulation d'actions propres Nouveau dénominateur [...]
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
31/01/2019
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in treating Clostridium [...]

Pages